Cryptococcosis

Disease Description (Causes and Symptoms)

• Definition: A fungal infection (cryptococcosis) caused by Cryptococcus neoformans or, rarely, C. gattii. Spores may be inhaled into the lungs, causing a localized pulmonary infection, or spread hematogenously to involve the central nervous system (especially the meninges), skin, and systemic organs.
• Causes/Pathophysiology: Inhalation of spores found mainly in bird droppings (especially pigeons) or contaminated soil → colonization of the lungs → localized symptoms or hematogenous dissemination. The risk of severe and disseminated disease is higher in immunocompromised individuals (HIV/AIDS, use of immunosuppressants, transplant recipients, diabetes, etc.).
• Major symptoms: Fever, headache, neck stiffness (in meningitis), respiratory symptoms (cough and shortness of breath, often mild), chest pain, and skin lesions (nodules and ulcers), among others. In meningitis, decreased consciousness, vomiting, visual disturbances, optic nerve lesions, and difficulty bending the neck (neck stiffness) may occur.

Treatment Methods and Precautions

• Diagnostic tests (before treatment): Serum/cerebrospinal fluid (CSF) cryptococcal antigen (CrAg) testing (high sensitivity), CSF bacterial culture and organism identification, CSF cell count, protein, and glucose tests, India ink staining (low sensitivity), chest X-ray/CT, and brain MRI/CT (to check for brain invasion and hydrocephalus).
• Summary of standard treatment (varies according to severity, lesion location, and immune status):
  • Cryptococcal meningitis (including in immunocompromised individuals): Induction therapy - combination of amphotericin B (deoxycholate or liposomal formulation) + flucytosine (generally for 2 weeks) → if consolidation therapy fails or resources are limited, WHO-recommended alternative therapy (amphotericin B alone or combined with high-dose fluconazole) → after consolidation, consolidation therapy: high-dose fluconazole (e.g., 400–800 mg/day) for 8 weeks → maintenance therapy: fluconazole 200 mg/day (until immune recovery or the risk of relapse has resolved).
  • Localized pulmonary infection (mild, immunocompetent): May be treated with oral fluconazole (e.g., for 6–12 months).
  • Severe pneumonia or disseminated/nonmeningeal systemic infection: Induction therapy with amphotericin B ± flucytosine, followed by a switch to fluconazole.
• Intracranial pressure management: Increased intracranial pressure is common in meningitis, so decompression with repeated lumbar punctures (in cases of severe headache, visual disturbances, or vomiting) may be performed, or a shunt (e.g., ventriculoperitoneal shunt) may be considered if continuous drainage is necessary.
• Medication monitoring and adverse effects:
  • Amphotericin B: Nephrotoxicity (increased creatinine), hypokalemia, and hypomagnesemia; monitoring of renal function and electrolytes is essential. The liposomal formulation is less nephrotoxic.
  • Flucytosine: Bone marrow suppression (decreased white blood cells and platelets) and abnormal liver function; blood levels and hematologic monitoring are required.
  • Fluconazole: Be aware of elevated liver enzymes and drug interactions (CYP inhibition). High-dose use during pregnancy may be dangerous (consult a doctor).
• Timing of starting antiretroviral therapy (ART) in people with HIV infection: In patients with meningitis, early ART (within one week) increases the risk of immune reconstitution inflammatory syndrome (IRIS), so ART is generally recommended within 4–6 weeks after starting antifungal treatment (adjusted according to the patient's condition and guidelines).
• Lifestyle management/precautions: Immunocompromised individuals (especially those with low CD4 counts) should minimize exposure to bird droppings and contaminated soil and follow general infection-control measures, such as refraining from smoking and limiting alcohol. Have regular tests (blood, kidney function, and liver function) while taking antifungal medications.

Checklist Before an Outpatient Visit (Items to Bring, Records, and Example Questions)

• Items/information to bring:
  • List of currently used medications (prescription drugs, OTC medications, and supplements)
  • Records of medication allergies and previous adverse effects
  • Existing medical certificates/reports and recent blood tests (CBC, kidney and liver function), CD4 count, and HIV viral load (if applicable)
  • Recent chest X-ray/CT and brain CT/MRI results (if available)
  • Record of when symptoms began and how they have changed (fever, headache severity, visual changes, shortness of breath, etc.)
  • Possibility of pregnancy (for women of childbearing potential, confirm whether pregnant)
• Information useful to provide to the doctor during the outpatient visit: Recent lumbar puncture results (CSF tests), CrAg test results (serum/CSF), and culture results.

Examples of General Questions to Ask the Doctor

• What are the major adverse effects of this medication, and how will they be monitored?
• Does my condition require inpatient treatment? Is outpatient treatment also possible?
• How long will treatment last? How high is the risk of relapse?
• Are there any medications that I need to stop or change because of drug interactions?
• What treatment is recommended if I am pregnant or planning to become pregnant?

Examples of Disease-Specific Questions

• Regarding meningitis: "How will you determine whether my intracranial pressure is currently elevated, and if it is elevated, what type of decompression treatment will be used (repeated lumbar punctures vs. a shunt)?"
• Regarding monitoring during treatment: "When amphotericin B or flucytosine is administered, which tests should be performed and at what intervals (kidney function, electrolytes, blood cell counts, etc.)?"

(If necessary, providing diagnostic test results, HIV status, and current medication details can help you receive more specific consultation and a treatment plan.)